BackForte Biosciences Overview
Forte Biosciences Inc

Forte Biosciences P/E Ratio

Latest P/E ratio for Forte Biosciences: -16.76 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-16.76

P/E Ratio

-16.76

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Forte Biosciences (FBRX) FAQ

Forte Biosciences (FBRX) currently reports a P/E ratio of -16.76. That is below the Healthcare sector average of 26.85. Use the charts on this page to explore Forte Biosciences's P/E ratio history and peer comparisons.

Forte Biosciences's P/E ratio of -16.76 is lower than the Healthcare sector average of 26.85. That is roughly 162.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Forte Biosciences's market price to a fundamental measure such as earnings, sales, or book value. At -16.76, FBRX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -16.76, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.85. From there, open related valuation or income-statement pages for Forte Biosciences, and consider following FBRX for alerts when major investors trade the stock.

Forte Biosciences is classified in the Healthcare sector. On P/E ratio, it currently shows -16.76 versus a sector average near 26.85. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FBRX with unrelated industries.